Urinary Prostate-specific antigen and Microseminoprotein-beta levels in men with and without prostate cancer: A prospective study of 60 cases in Indian population.

DR SHREENATH PATIL; DR AKASH BANDE; DR YOGENDRA CHIDRAWAR

Volume : IX, Issue : II, February - 2020

Urinary Prostate-specific antigen and Microseminoprotein-beta levels in men with and without prostate cancer: A prospective study of 60 cases in Indian population.

Dr Shreenath Patil, Dr Akash Bande, Dr Yogendra Chidrawar

Abstract :

Background: The role of urinary proteomics in the diagnosis of prostate cancer (PC) is undefined. Levels of urinary biomarkers such as prostate‑specific antigen (PSA) and microseminoprotein‑beta (MSMB) may differ between men with and without PC. We tested this hypothesis using urine samples before and after digital rectal examination (DRE) in men with an indication for prostate biopsy. Methods: This prospective study was performed after all individuals provided informed consent for inclusion, men with elevated PSA or a nodule on DRE underwent a pre and post‑DRE urine sample examination for urinary PSA and MSMB levels. Levels were compared between men who had PC diagnosed on biopsy (Group A) and those with a negative biopsy (Group B). Results: A total of 60 patients were included in the study, 2 patients had very high serum PSA values (2315 and 1699 ng/ml) and were excluded from the analysis as outliers. 58 patients were included of whom 21 had PC (Group A) and 37 had no cancer (Group B) on biopsy. The median urine PSA (25.4 vs 22.3 mg/dl) and MSMB (1.9 vs. 1.2 mg/dl) were almost similar in both groups at baseline. However, Both urinary PSA and MSMB values rose significantly after DRE in Group B (median urinary PSA from 22.3 to 99.2 mg/dl; median urinary MSMB from 1.2 to 4.3 mg/dl) but not in Group A (median urinary PSA from 25.4 to 24.1 mg/dl; median urinary MSMB from 1.9 to 3.1 mg/dl) Conclusions: Urinary PSA and MSMB rose significantly after DRE only in men without PC. Post‑DRE urine PSA and MSMB can differentiate PC from benign pathology in men with an indication for prostate biopsy.